Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug

Resumen detallado
Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab. The post Summit Crumbles After FDA…
Summit Therapeutics (SMMT) stock crashed Monday after the Food and Drug Administration rejected its Merck (MRK)-rivaling lung cancer drug, ivonescimab. Leerink Partners analyst Daina Graybosch wasn't surprised, noting the FDA said ivonescimab in combination with chemotherapy would need to improve overall survival to win approval. Overall survival is how long patients live before dying of any cause. The regimen failed…
Inicio del artículo, extracto de Investor's Business Daily. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.investors.com)